title: Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
authors.affiliation: Sharp Memorial Heart Transplant Center, San Diego, California, USA.
authors.forename: R
authors.initials: R
authors.lastname: Adamson
authors.forename: E
authors.initials: E
authors.lastname: Obispo
authors.forename: S
authors.initials: S
authors.lastname: Dychter
authors.forename: W
authors.initials: W
authors.lastname: Dembitsky
authors.forename: R
authors.initials: R
authors.lastname: Moreno-Cabral
authors.forename: B
authors.initials: B
authors.lastname: Jaski
authors.forename: J
authors.initials: J
authors.lastname: Gordon
authors.forename: P
authors.initials: P
authors.lastname: Hoagland
authors.forename: K
authors.initials: K
authors.lastname: Moore
authors.forename: J
authors.initials: J
authors.lastname: King
authors.forename: J
authors.initials: J
authors.lastname: Andrews
authors.forename: M
authors.initials: M
authors.lastname: Rich
authors.forename: P O
authors.initials: PO
authors.lastname: Daily
mesh_terms: D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D001379:Azathioprine